A5002925030- Migraine and Headache Studies
- Traumatic Brain Injury Research
- Trigeminal Neuralgia and Treatments
- Cannabis and Cannabinoid Research
- Botulinum Toxin and Related Neurological Disorders
- Spinal Dysraphism and Malformations
- Cardiovascular Syncope and Autonomic Disorders
- Cerebrospinal fluid and hydrocephalus
- Transcranial Magnetic Stimulation Studies
- Traumatic Brain Injury and Neurovascular Disturbances
- Neurological Complications and Syndromes
- Neurological Disorders and Treatments
- Psychosomatic Disorders and Their Treatments
- Biomedical and Chemical Research
- Transportation Systems and Infrastructure
- Neurological disorders and treatments
- Genetic Neurodegenerative Diseases
- Fetal and Pediatric Neurological Disorders
- Biochemical and Molecular Research
- Teratomas and Epidermoid Cysts
- Spine and Intervertebral Disc Pathology
- Body Image and Dysmorphia Studies
- Traumatic Ocular and Foreign Body Injuries
- Attention Deficit Hyperactivity Disorder
- Pediatric Pain Management Techniques
Dent Neurologic Institute
2013-2025
University at Buffalo, State University of New York
2021
Background: OnabotulinumtoxinA and calcitonin gene-related peptide (CGRP) monoclonal antibodies (mAbs) target different migraine pathways, therefore, combination treatment may provide additional effectiveness for the preventive of chronic (CM) than either alone. The objective this study was to collect real-world data improve understanding safety, tolerability, adding a CGRP mAb onabotulinumtoxinA CM. Methods: This retrospective, longitudinal conducted using extracted from single clinical...
Background Atogepant is a United States Food and Drug Administration-approved oral calcitonin gene-related peptide receptor antagonist for the preventive treatment of episodic migraine. The study objective was to evaluate long-term safety tolerability atogepant in participants who completed phase 3 ADVANCE trial (NCT03777059). Methods This 40-week, open-label extension (NCT03939312) monitored receiving 60 mg once daily, followed by four-week follow-up period. Results Of 685 taking at least...
Abstract Erenumab, a fully human monoclonal antibody targeting the calcitonin gene‐related peptide receptor, is efficacious and safe for prevention of attacks migraine in adults. This phase I, randomized, open‐label, multiple‐dose study evaluated safety, tolerability, pharmacokinetics (PK) erenumab children adolescents with migraine. The initial treatment lasted 12 weeks, followed by an optional 40‐week extension adolescents. Primary end points were PK erenumab, incidence treatment‐emergent...
Fremanezumab, a monoclonal antibody (mAb) targeting the calcitonin gene-related peptide (CGRP) pathway, and gepants, small molecule CGRP receptor antagonists, are both approved for treatment of migraine or its symptoms. This study assessed effectiveness, tolerability, migraine-related healthcare resource utilization (HCRU) after addition fremanezumab preventive in patients using gepants acute treatment. Data were extracted during retrospective chart review from electronic medical records...
Abstract Background Conventional, non-specific preventive migraine treatments often demonstrate low rates of treatment persistence due to poor efficacy or tolerability. Effective, well-tolerated are needed reduce symptoms, improve function, and enhance quality life. Atogepant is a migraine-specific oral calcitonin gene–related peptide receptor antagonist that indicated for the in adults. This analysis evaluated safety tolerability profile atogepant migraine, including adverse events (AEs)...
BACKGROUND: Chronic migraine (CM) is a common neurologic disorder that imposes substantial burden on payers, patients, and society. Low rates of persistence to oral preventive medications have been previously documented; however, less known about costs associated with innovative nonoral medications.
Abstract Objective There is an unmet need for new, efficacious, well-tolerated, acute treatments migraine in adolescents. Remote electrical neuromodulation (REN) a novel, nonpharmacological treatment that provides significant symptom relief with good tolerability. The current post hoc analysis compared the efficacy of REN to standard-care medications Design Within-participant data from clinical trial. Setting Data Subjects 35 adolescent participants were analyzed. Methods Efficacy was...
Atogepant is an oral, small-molecule, calcitonin gene-related peptide receptor antagonist for the preventive treatment of episodic migraine.In this 52-week, multicenter, randomized, open-label trial, adults with 4-14 monthly migraine days received atogepant 60 mg once-daily or standard care. Health outcome endpoints collected from participants randomized to included change baseline in Migraine-Specific Quality Life Questionnaire version 2.1 (MSQ v2.1) Role Function-Restrictive (RFR),...
Objective: Evaluate efficacy and safety of medical cannabis (MC) for pain epilepsy in patients with autism spectrum disorder (ASD). Background: MC is approved treatment ASD 14 states (not NY). In NY it pain. Common challenges include aggression, self-injurious behavior (SIB), elopement, pain, epilepsy. Some individuals can also have severe symptoms. Most these try multiple medications concerning side effects (SE). This study reports a case series treated MC. Design/Methods: Retrospective...
Abstract Objective To evaluate the efficacy and safety of zolmitriptan nasal spray (ZNS) in acute treatment migraine headache patients aged 6 to 11 years. Background Triptans have demonstrated adults, but pediatric studies these agents largely failed there are few triptan options for patients. Because lack response 1 does not necessarily preclude an alternate triptan, additional desirable. Methods This Phase 3, randomized, double‐blind, placebo‐controlled, multicenter crossover trial with...
Background: Balance and proprioception are essential elements in postural control injury prevention. Proprioception, the body’s sense of position movement, is closely tied to balance, which depends on input from visual, vestibular, somatosensory systems. This article explores link between trauma experiences proprioceptive dysfunction, emphasizing how heightened muscle tone, dissociation, altered sensory processing contribute balance issues risk injury. Method: The study included 48...
Objective: Examine medical cannabis (MC) as treatment for concussion-related chronic pain in an established MC clinic. Background: Individuals with concussion often experience discomfort from post-traumatic headaches. was approved use by New York State March 2017. DENT has treated 5,260 patients MC, including 4,017 and 399 symptoms. Design/Methods: A retrospective analysis of active (N=70) those without (N=33) conducted. In total, 103 charts were reviewed, a total 150 expected presentation...
Objective To evaluate the pharmacokinetics, safety, and tolerability of a single 50‐mg oral dose diclofenac potassium for solution (OS) in pediatric cohort with diagnosis episodic migraine; 3‐month safety trial following an outpatient dosing period was also evaluated. Background Children adolescents often experience migraine pain that is poorly controlled, which may affect their emotional psychological well‐being. Diclofenac OS approved treatment aura (MWA) or without (MWoA) adults 18 years...
Investigate the efficacy of 3 anti-Calcitonin Gene-Related Peptide monoclonal antibodies (anti-CGRP mAbs), fremanezumab, galcanezumab, and erenumab, in concussion patients with post-traumatic headache (PTH) a migraine phenotype.A study using mice mild traumatic brain injury saw improvements cutaneous allodynia.1 A from Denmark erenumab for PTH found had an 82% decrease number days. This also demonstrated that 44% reduction HIT-6 score = 5 after 9-12 weeks treatment.2.Retrospective chart...
Evaluate real-world persistence rates and costs among patients with chronic migraine (CM) treated onabotulinumtoxinA (onabotA [BOTOX®]) or calcitonin gene–related peptide monoclonal antibody (CGRP mAb).